NVAX (Novavax) Other Stockholders Equity: $-0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVAX Novavax Inc NVAX
42 GF Score
Price $7.92
GF Value $3.26
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Novavax Other Stockholders Equity?

Novavax NVAX +0.38% 42 Other Stockholders Equity is $-0.0 Mil as of Jun. 2026. GuruFocus rates NVAX with a GF Score™ of 42/100 and a GF Value™ of $3.26 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Novavax's Other Stockholders Equity for the quarter that ended in Jun. 2026 was $-0.0 Mil.

Novavax's quarterly Other Stockholders Equity increased from Dec. 2025 ($0.0 Mil) to Mar. 2026 ($0.0 Mil) but then declined from Mar. 2026 ($0.0 Mil) to Jun. 2026 ($-0.0 Mil).

Novavax's annual Other Stockholders Equity declined from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($-0.0 Mil) but then increased from Dec. 2024 ($-0.0 Mil) to Dec. 2025 ($0.0 Mil).

Novavax Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Novavax's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Other Stockholders Equity Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.00 0.00 -0.00 0.00

Novavax Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 0.00 0.00 -0.00
NVAX
42GF Score
Novavax Inc NVAX
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $-0.0 Mil mean?
Novavax (NVAX) has a Other Stockholders Equity of $-0.0 Mil as of Jun. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Novavax and its competitors.
Is Novavax's Other Stockholders Equity too high?
Novavax's current Other Stockholders Equity is $-0.0 Mil. Overall, Novavax has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Other Stockholders Equity compare to JBIO and AVLN?
Novavax's Other Stockholders Equity of $-0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Novavax and its competitors. Novavax's current Other Stockholders Equity is $-0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.26, compared to a current price of $7.92 — trading 142.9% above its estimated fair value. The current Other Stockholders Equity is $-0.0 Mil. Novavax's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Novavax (NVAX), the current Other Stockholders Equity is $-0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of $7.92 is trading 142.9% above its estimated GF Value™ of $3.26. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for NVAX:

  • Other Stockholders Equity: $-0.0 Mil
  • GF Value™: $3.26 vs. price of $7.92 (142.9% above fair value)
  • GF Score™: 42/100 with 5 warning signs

No single metric tells the full story. See the NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
42GF Score

Get the complete analysis for NVAX

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.92
Price
$3.26
GF Value